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Zeolite Nanoparticles for Selective 
Sorption of Plasma Proteins
M. Rahimi1,*, E.-P. Ng2,*, K. Bakhtiari3,4, M. Vinciguerra5, H. Ali Ahmad6, H. Awala6, 
S. Mintova6, M. Daghighi7, F. Bakhshandeh Rostami8, M. de Vries9, M. M. Motazacker10, 
M. P. Peppelenbosch11,*, M. Mahmoudi12,13,* & F. Rezaee9,11
The affinity of zeolite nanoparticles (diameter of 8–12 nm) possessing high surface area and high pore 
volume towards human plasma proteins has been investigated. The protein composition (corona) of 
zeolite nanoparticles has been shown to be more dependent on the plasma protein concentrations 
and the type of zeolites than zeolite nanoparticles concentration. The number of proteins present 
in the corona of zeolite nanoparticles at 100% plasma (in vivo state) is less than with 10% plasma 
exposure. This could be due to a competition between the proteins to occupy the corona of the 
zeolite nanoparticles. Moreover, a high selective adsorption for apolipoprotein C-III (APOC-III) and 
fibrinogen on the zeolite nanoparticles at high plasma concentration (100%) was observed. While the 
zeolite nanoparticles exposed to low plasma concentration (10%) exhibited a high selective adsorption 
for immunoglobulin gamma (i.e. IGHG1, IGHG2 and IGHG4) proteins. The zeolite nanoparticles can 
potentially be used for selectively capture of APOC-III in order to reduce the activation of lipoprotein 
lipase inhibition during hypertriglyceridemia treatment. The zeolite nanoparticles can be adapted to 
hemophilic patients (hemophilia A (F-VIII deficient) and hemophilia B (F-IX deficient)) with a risk of 
bleeding, and thus might be potentially used in combination with the existing therapy.
Zeolites are low-density crystalline aluminosilicates possessing regular micropores (one-, two- and 
three-dimensional) with well-defined pore sizes and shapes. The well-defined structures of zeolites com-
bine with hydrophilic/hydrophobic and porous nature render them as useful shape-selective molecu-
lar sieves and hosts for various guest molecules (organic and inorganic). A significant effort has been 
devoted to the preparation of zeolites with nanometer dimensions with enhanced accessibility of reactant 
molecules in order to achieve higher product yield/selectivity in catalytic reactions or fast diffusion in 
adsorption and ion exchanged processes1,2. In addition to the regular micropores, the zeolites nanopar-
ticles contain meso- and macro-pores due to the close packing of homogeneous in size and morphology 
crystals. Additionally, the zeolite nanoparticles with a size smaller than 200 nm can be stabilized in 
suspensions with different concentrations that are colloidal stable and do not agglomerate with time2. 
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Therefore, aluminosilicate and pure silicate zeolite nanoparticles are safely applied in protein adsorption 
for organ transplantation3, hemostatic material for wound healing4, MRI contrasting agent5, antibacterial 
agents6 and drug delivery7. Moreover, the immobilization of biomolecules on the well-developed external 
surface of zeolite nanoparticles is the focus of intense activity in biotechnology and biomedicine8–10.
EMT- and FAU-type zeolites have very low framework density (FD = 12.7‒12.9 T/1000 Å), high 
porosity, diverse morphology and crystal sizes11. Unlike its cubic FAU polymorph that has only super-
cages (1.15 nm3), the EMT-zeolite has two cages: hypocage (0.61 nm3) and hypercage (1.24 nm3) due to 
different stacking of faujasite sheets. As a result, it creates different catalytic and sorption properties for 
both materials11.
Recently, it was reported that the large pore EMT-type nanosized zeolite can adsorb fibrinogen and 
apolipoproteins while keeping the same amount of albumin in human plasma12. Fibrinogen is a very com-
plex, hydrophilic and bipolar molecule13–18. In opposite to fibrinogen, apolipoprotein C-III (APOC-III) is 
a simple, highly hydrophobic and non-polar molecule with a molecular weight of approximately 11 kDa. 
APOC-III inhibits very low-density lipoproteins (VLDL)-triglycerides, hepatic lipase (HL), and lipopro-
tein lipase (LPL) functions; the major function of LPL is to hydrolyze chylomicrons (CMs). As a result, 
the inhibition of LPL leads in the delay of degradation of triglyceride-rich particles (i.e. CM and VLDL), 
which is implicated in pathophysiological events such as cardiovascular diseases19–24.
The adsorption specificity of proteins has been studied for several nanoparticles including gold, super 
paramagnetic iron oxide, silica, and polystyrene25–30. However, to our best knowledge, the adsorption 
specificity of proteins on zeolite nanoparticles has not been investigated so far. As a result, it hampers 
the development of rational targets for biomedical applications of zeolite nanoparticles.
The aim of this paper is to study the selective sorption behavior of nanosized EMT- and FAU-zeolites 
for human plasma proteins with different concentrations of either the zeolites or the human plasma 
proteins.
Results
Characterization of EMT- and FAU-zeolite nanoparticles. High-resolution transmission electron 
microscopy (HR-TEM) and dynamic light scattering (DLS) were used to study the size and morphology 
of the zeolite nanocrystals. Discrete octahedral FAU- and hexagonal EMT- zeolite nanocrystals with an 
average diameter in the range of 8–12 nm are shown in Figure 1. Both the EMT- and FAU- zeolite nano-
crystals have well developed crystalline faces. Moreover they appear as single crystals, and no crystals 
intergrowth was observed, which is in a good accordance with the zeta potential measurements and 
scanning electron microscopy study (Figure S1). The zeta potential values measured for the EMT- and 
FAU- zeolite nanoparticles of − 44 and − 50 mV, respectively, correspond to colloidal samples containing 
highly stable non-agglomerated crystals (Figure 1). On the other side the negative zeta potential value 
represent particles with negative surface charge. The surface charges of the zeolite nanoparticles are 
expected to play an important role in the interactions with human plasma proteins. Therefore the sur-
face charge and charge density of both zeolite nanoparticles were determined. Both samples have almost 
identical surface charge density, i.e., − 0.50 mC/m2 and − 0.58 mC/m2 for EMT- and FAU- zeolite crystals 
respectively (Table  1a), while the surface charge of FAU- zeolite nanoparticles is higher (− 299 mC/g) 
Figure 1. (a) Zeta potential curves of EMT- and FAU-zeolite suspensions, and transmission electron 
micrographs of (b) EMT- and (c) FAU-zeolite nanoparticles.
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Zeolites Si/Al ratio Chemical composition
SBET 
(m2/g)a
SExternal 
(m2/g)b
VTotal 
(cm3/
g)c
Surface 
charge  
(mC/g)
Surface charge 
density  
(mC/m2)
Zeta potential 
(mV)
(a) Physicochemical properties of EMT- and FAU- type zeolites. aSpecific BET surface area; bExternal surface area; cTotal pore volume
EMT 1.18 Na88(AlO2)88(SiO2)104 570 220 0.89 − 235 − 0.50 − 44
FAU 1.63 Na73(AlO2)73(SiO2)119 845 235 1.27 − 229 − 0.58 − 50
Accession Description Mw
–10l gP Spectra NpSpCk Average 
NpSpCkS 1 S 2 S 1 S 2 S 1 S 2
(b) (12% EMT + 100% human plasma)
P02656|APOC3_HUMAN Apolipoprotein C-III OS = Homo sapiens GN = APOC3 PE = 1 SV = 1 10852 189.29 177.2 5 6 27.59 25.75 26.67
P02671|FIBA_HUMAN Fibrinogen alpha chain OS = Homo sapiens GN = FGA PE = 1 SV = 2 94973 414.34 334.15 29 29 18.28 14.22 16.25
P02679|FIBG_HUMAN Fibrinogen gamma chain OS = Homo sapiens GN = FGG PE = 1 SV = 3 51512 314.11 283.84 13 14 15.11 12.66 13.88
P02675|FIBB_HUMAN Fibrinogen beta chain OS = Homo sapiens GN = FGB PE = 1 SV = 2 55928 284.67 200.7 9 13 9.64 10.83 10.23
P02768|ALBU_HUMAN Serum albumin OS = Homo sapiens GN = ALB PE = 1 SV = 2 69367 326.93 334.97 11 16 9.50 10.74 10.12
P02647|APOA1_HUMAN Apolipoprotein A-I OS = Homo sapiens GN = APOA1 PE = 1 SV = 1 30778 160.72 166.71 2 5 3.89 7.57 5.73
P19823|ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 OS = Homo sapiens GN = ITIH2 PE = 1 SV = 2 106463 130.81 229.14 7 8 3.94 3.50 3.72
P04004|VTNC_HUMAN Vitronectin OS = Homo sapiens GN = VTN PE = 1 SV = 1 54306 198.44 111.32 3 3 3.31 2.57 2.94
P01024|CO3_HUMAN Complement C3 OS = Homo sapiens GN = C3 PE = 1 SV = 2 187147 373.99 365.84 9 11 2.88 2.74 2.81
P04003|C4BPA_HUMAN C4b-binding protein alpha chain OS = Homo sapiens GN = C4BPA PE = 1 SV = 2 67033 92.93 53.7 2 2 1.79 1.39 1.59
P01857|IGHG1_HUMAN Ig gamma-1 chain C region OS = Homo sapiens GN = IGHG1 PE = 1 SV = 1 36106 ND 96.97 0 2 0.00 2.58 1.29
P04114|APOB_HUMAN Apolipoprotein B-100 OS = Homo sapiens GN = APOB PE = 1 SV = 2 515611 238.42 208.01 10 9 1.16 0.81 0.99
P02748|CO9_HUMAN Complement component C9 OS = Homo sapiens GN = C9 PE = 1 SV = 2 63173 ND 62.79 0 2 0.00 1.47 0.74
P00751|CFAB_HUMAN Complement factor B OS = Homo sapiens GN = CFB PE = 1 SV = 2 85533 45.2 ND 2 0 1.40 0.00 0.70
P02787|TRFE_HUMAN Serotransferrin OS = Homo sapiens GN = TF PE = 1 SV = 3 77064 36.21 95.17 1 1 0.78 0.60 0.69
P02749|APOH_HUMAN Beta-2-glycoprotein 1 OS = Homo sapiens GN = APOH PE = 1 SV = 3 38298 ND 55.03 0 1 0.00 1.22 0.61
P00736|C1R_HUMAN Complement C1r subcomponent OS = Homo sapiens GN = C1R PE = 1 SV = 2 80119 74.95 ND 1 0 0.75 0.00 0.37
P07358|CO8B_HUMAN Complement component C8 beta chain OS = Homo sapiens GN = C8B PE = 1 SV = 3 67047 ND 76.88 0 1 0.00 0.69 0.35
P01042|KNG1_HUMAN Kininogen-1 OS = Homo sapiens GN = KNG1 PE = 1 SV = 2 71957 ND 44.95 0 1 0.00 0.65 0.32
(c) (12% FAU + 100% human plasma)
P02656|APOC3_HUMAN Apolipoprotein C-III OS = Homo sapiens GN = APOC3 PE = 1 SV = 1 10852 259.65 263.71 12 6 22.68 23.56 23.12
P02679|FIBG_HUMAN Fibrinogen gamma chain OS = Homo sapiens GN = FGG PE = 1 SV = 3 51512 384.9 282.85 27 11 10.75 9.10 9.92
P02671|FIBA_HUMAN Fibrinogen alpha chain OS = Homo sapiens GN = FGA PE = 1 SV = 2 94973 367.67 281.85 43 23 9.29 10.32 9.80
P02768|ALBU_HUMAN Serum albumin OS = Homo sapiens GN = ALB PE = 1 SV = 2 69367 372.84 333.91 34 15 10.05 9.21 9.63
P02675|FIBB_HUMAN Fibrinogen beta chain OS = Homo sapiens GN = FGB PE = 1 SV = 2 55928 340.52 209.02 22 11 8.07 8.38 8.22
P19827|ITIH1_HUMAN Inter-alpha-trypsin inhibitor heavy chain H1 OS = Homo sapiens GN = ITIH1 PE = 1 SV = 3 101389 378.57 407.28 28 21 5.66 8.82 7.24
P19823|ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 OS = Homo sapiens GN = ITIH2 PE = 1 SV = 2 106463 365.4 346.93 21 22 4.05 8.80 6.42
P04004|VTNC_HUMAN Vitronectin OS = Homo sapiens GN = VTN PE = 1 SV = 1 54306 251.16 262.66 10 5 3.78 3.92 3.85
Continued
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P02647|APOA1_HUMAN Apolipoprotein A-I OS = Homo sapiens GN = APOA1 PE = 1 SV = 1 30778 166.81 161.68 5 2 3.33 2.77 3.05
P00747|PLMN_HUMAN Plasminogen OS = Homo sapiens GN = PLG PE = 1 SV = 2 90569 233.27 171.78 8 8 1.81 3.76 2.79
P01024|CO3_HUMAN Complement C3 OS = Homo sapiens GN = C3 PE = 1 SV = 2 187147 426.87 386.41 20 12 2.19 2.73 2.46
P02649|APOE_HUMAN Apolipoprotein E OS = Homo sapiens GN = APOE PE = 1 SV = 1 36154 170.95 ND 4 0 2.27 0.00 1.13
P02760|AMBP_HUMAN Protein AMBP OS = Homo sapiens GN = AMBP PE = 1 SV = 1 39000 ND 58.57 0 2 0.00 2.18 1.09
P0C0L4|CO4A_HUMAN Complement C4-A OS = Homo sapiens GN = C4A PE = 1 SV = 1 192770 203.76 143.77 8 5 0.85 1.11 0.98
P0C0L5|CO4B_HUMAN Complement C4-B OS = Homo sapiens GN = C4B PE = 1 SV = 1 192792 203.76 143.77 8 5 0.85 1.10 0.98
P01042|KNG1_HUMAN Kininogen-1 OS = Homo sapiens GN = KNG1 PE = 1 SV = 2 71957 135.73 78.39 4 1 1.14 0.59 0.87
P02765|FETUA_HUMAN Alpha-2-HS-glycoprotein OS = Homo sapiens GN = AHSG PE = 1 SV = 1 39325 183.38 ND 3 0 1.56 0.00 0.78
P00450|CERU_HUMAN Ceruloplasmin OS = Homo sapiens GN = CP PE = 1 SV = 1 122205 134.61 71.87 5 2 0.84 0.70 0.77
P04114|APOB_HUMAN Apolipoprotein B-100 OS = Homo sapiens GN = APOB PE = 1 SV = 2 515611 232.58 238.32 12 12 0.48 0.99 0.73
P35542|SAA4_HUMAN Serum amyloid A-4 protein OS = Homo sapiens GN = SAA4 PE = 1 SV = 2 14747 124.34 ND 1 0 1.39 0.00 0.70
P07358|CO8B_HUMAN Complement component C8 beta chain OS = Homo sapiens GN = C8B PE = 1 SV = 3 67047 160.9 ND 4 0 1.22 0.00 0.61
P00751|CFAB_HUMAN Complement factor B OS = Homo sapiens GN = CFB PE = 1 SV = 2 85533 98.7 ND 5 0 1.20 0.00 0.60
P04196|HRG_HUMAN Histidine-rich glycoprotein OS = Homo sapiens GN = HRG PE = 1 SV = 1 59578 45.77 ND 3 0 1.03 0.00 0.52
P07360|CO8G_HUMAN Complement component C8 gamma chain OS = Homo sapiens GN = C8G PE = 1 SV = 3 22277 94.8 ND 1 0 0.92 0.00 0.46
P00738|HPT_HUMAN Haptoglobin OS = Homo sapiens GN = HP PE = 1 SV = 1 45205 36.07 ND 2 0 0.91 0.00 0.45
P13671|CO6_HUMAN Complement component C6 OS = Homo sapiens GN = C6 PE = 1 SV = 3 104786 ND 56.49 0 2 0.00 0.81 0.41
Q9H6K5|YS027_HUMAN Putative uncharacterized protein FLJ22184 OS = Homo sapiens PE = 1 SV = 1 60039 35.56 ND 2 0 0.68 0.00 0.34
P04003|C4BPA_HUMAN C4b-binding protein alpha chain OS = Homo sapiens GN = C4BPA PE = 1 SV = 2 67033 ND 31.62 0 1 0.00 0.64 0.32
P00748|FA12_HUMAN Coagulation factor XII OS = Homo sapiens GN = F12 PE = 1 SV = 3 67792 90.73 ND 2 0 0.61 0.00 0.30
P08603|CFAH_HUMAN Complement factor H OS = Homo sapiens GN = CFH PE = 1 SV = 4 139096 111.35 ND 4 0 0.59 0.00 0.29
P02749|APOH_HUMAN Beta-2-glycoprotein 1 OS = Homo sapiens GN = APOH PE = 1 SV = 3 38298 72.34 ND 1 0 0.54 0.00 0.27
P06396|GELS_HUMAN Gelsolin OS = Homo sapiens GN = GSN PE = 1 SV = 1 85697 ND 36.85 0 1 0.00 0.50 0.25
Q14410|GLPK2_HUMAN Glycerol kinase 2 OS = Homo sapiens GN = GK2 PE = 2 SV = 2 60594 34.37 ND 1 0 0.34 0.00 0.17
P00734|THRB_HUMAN Prothrombin OS = Homo sapiens GN = F2 PE = 1 SV = 2 70037 64.19 ND 1 0 0.29 0.00 0.15
P00736|C1R_HUMAN Complement C1r subcomponent OS = Homo sapiens GN = C1R PE = 1 SV = 2 80119 79.24 ND 1 0 0.26 0.00 0.13
P49815|TSC2_HUMAN Tuberin OS = Homo sapiens GN = TSC2 PE = 1 SV = 2 200607 27.34 ND 2 0 0.20 0.00 0.10
Q96L96|ALPK3_HUMAN Alpha-protein kinase 3 OS = Homo sapiens GN = ALPK3 PE = 2 SV = 2 201270 37.91 ND 1 0 0.10 0.00 0.05
P02751|FINC_HUMAN Fibronectin OS = Homo sapiens GN = FN1 PE = 1 SV = 4 262622 42.55 ND 1 0 0.08 0.00 0.04
Table 1.  NLC-MS/MS combined with PEAKS DB analysis of the corona (protein content) and 
physicochemical properties of zeolite nanoparticles (NPs). Table 1a shows physicochemical surface 
properties of EMT and FAU zeolite NPs. Table 1b represents EMT zeolite NPs (12% EMT + 100% human 
plasma) and Table 1c is FAU zeolite NPs (12% FAU + 100% human plasma). The accession number, gene 
name, species (Human), protein description, identification score (-10lgP), molecular weight (Mw) in kDa, total 
spectra per protein of EMT (12%) and FAU (12%) zeolite NPs incubated with human plasma (100%), together 
with their relative amount (NpSpCk value). Sample (S). All protein coverage of different combination (EMT 
(%) and plasma (%), and (FAU (%) and plasma (%)) were reported in Supplementary Information.
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than the EMT- zeolite (− 235 mC/g) (Table 1a). This can be explained with the different specific surface 
area of the EMT- and FAU- zeolite nanocrystals (Table 1a). The surface charge of the zeolite nanoparti-
cles is negative, which is consistent with their high hydrophilicity. Additionally, the porosity of the zeolite 
nanocrystals was evaluated by nitrogen sorption measurements carried out at − 196 °C (Figure 2). The 
N2 sorption isotherms of both samples resembled Type I and Type IV isotherms, indicating the presence 
of micropores and mesopores (textural porosity); the mesopores with an average diameter of 25 nm are 
originated from the close packing of the zeolite nanocrystals. The results extracted from the N2 sorption 
isotherms for EMT- and FAU- zeolite nanoparticles are summarized in Table 1. The BET specific surface 
area of FAU- zeolite nanoparticles is 845 m2/g, which is higher than for the EMT- zeolite nanoparticles 
(570 m2/g). The external surface area of EMT- and FAU-zeolite nanoparticles is 220 m2/g and 235 m2/g, 
respectively, which contributed of approximately 30 - 40% of their specific surface area. In addition, 
both samples have high total pore volume, i.e., for the EMT zeolite is 0.89 cm3/g and for the FAU zeolite 
is 1.27 cm3/g, which will be further beneficial for the selective sorption toward human plasma proteins.
Semi-quantitative assessment of corona protein composition of EMT- and FAU- zeolite nano-
particles. Semi-quantitative equation is used to obtain information about the amount of each protein 
bound onto the surface of the EMT- and FAU- zeolite nanoparticles. All proteins identified in the exper-
iments are described in Supporting Information (SI). The semi-quantitative assessment of each protein, 
namely, the normalized percentage of the spectral count for protein k (NpSpCk), is determined based on 
the total number of all peptides that were attributed to a matched protein in the nLC-MS/MS spectra 
(Tables 1b,c; and SI: Tables S1 and S2).
The affinity of the EMT- and FAU- zeolite nanoparticles towards human plasma proteins was investi-
gated by incubating zeolite nanoparticles with plasma proteins using one of the following strategies: (1) 
the concentration of nanoparticles was kept constant but the plasma concentration was varied, and (2) 
the plasma concentration was kept constant but the concentration of zeolite nanoparticles was varied. 
The identification of proteins present on the surface of EMT- and FAU-zeolite nanoparticles (SI: Tables 
S1 and S2) was carried out using nLC-MS/MS (LTQ-ORBITRAP-XL; tandem mass spectrometry) com-
bined with PEAKS DB (software) analysis. The nLC-MS/MS results show that with increasing the plasma 
concentrations from 10% to 100%, the APOC-III and the three chains of fibrinogen (FIBA, FIBB and 
FIBG) are bound on the surface of the zeolite nanoparticles. The amount of adsorption was less depend-
ent on the concentration of zeolite nanoparticles than plasma concentrations used (Figures 3 and 4; and 
SI: Tables S1 and S2). After exposure of zeolite nanoparticles to very low plasma concentrations (10%), 
the zeolites exhibit a high affinity for immunoglobulin gamma (i.e. IGHG1, IGHG2 and IGHG4) as 
compared to the high plasma concentrations (Figures 3 and 4). Notably, upon using EMT-zeolite nano-
particles with 100% plasma, the APOC-III showed an adsorption of 30%. Furthermore, all three chains of 
fibrinogen (FIBA, FIBB, and FIBG) demonstrated a high affinity toward EMT-zeolite nanoparticles even 
at low concentrations (4‒12%) incubated with 10% plasma. As a representative example, the spectra of 
Fibrinogen α -chain and APOC-III after injection of the extracted peptides from EMT and FAU zeolite 
nanoparticles are depicted in Figure 5 (a,b).
Interaction of APOC-III and fibrinogen with EMT- and FAU-zeolite nanoparticles. The 
APOC-III is adsorbed on the surface of both EMT- and FAU-zeolite nanoparticles (Figure S2). The 
positively charged amino acid residues of APOC-III and the negatively charged EMT- and FAU-zeolite 
Figure 2. Nitrogen adsorption (closed symbol) and desorption (open symbol) isotherms of (a) EMT- and 
(b) FAU-zeolite nanoparticles. Inset: schematic presentation of the framework type of (a) EMT- and (b) 
FAU-zeolites, which can be described by the stacking of sodalite layers, resulting in ABABAB and ABCABC 
sequences, respectively.
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nanoparticles facilitate the electrostatic interactions and thus the adsorption of APOC-III on the zeolite 
surfaces. Fibrinogen is a bipolar molecule with negatively charged E and D domains, and positively 
charged α C-domain (PDB entry: 3GHG; Figure  6a). The α C-domain of fibrinogen Aα -chain (starts 
from amino acid 392 to 610) is highly flexible, mobile and positively charged31–34. This region shows 
positive electrostatic character, which is potentially responsible for the interaction between the fibrinogen 
and the negatively charged EMT- and FAU-zeolite nanoparticles. A schematic diagram of human fibrin-
ogen structure and a flexible α C-domain of the fibrinogen are depicted in Figure 6b.
Effect of EMT- and FAU-zeolite nanoparticles on blood coagulation. Fibrinogen is a glycopro-
tein that helps in the formation in blood clots. Since the fibrinogen has strong tendency to bind to both 
zeolite nanoparticles, thus it is very important to investigate their effect on clotting time. In respect to 
this, coagulometer was applied to determine prothrombin time (PT), i.e., a test that measures how long 
it takes the blood to clot. Without adding zeolite nanoparticles, the thrombin time is 23 sec (Figure 7). 
Figure 3. nLC-MS/MS analysis of corona-associated proteins on EMT-zeolite nanoparticles. 
Apolipoprotein C-III (APOC-III), fibrinogen alpha chain (FIBA), fibrinogen beta chain (FIBB), fibrinogen 
gamma chain (FIBG), albumin (ALBU), IGHG1, IGHG2 and IGHG4.
Figure 4. nLC-MS/MS analysis of corona-associated proteins on FAU-zeolite nanoparticles. 
Apolipoprotein C-III (APOC-III), fibrinogen alpha chain (FIBA), fibrinogen beta chain (FIBB), fibrinogen 
gamma chain (FIBG), albumin (ALBU), IGHG1, IGHG2 and IGHG4.
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Figure 5. Representative nLC-MS/MS spectra of (a) fibrinogen α-chain after injection of extracted peptides 
from EMT- zeolite nanoparticles, and (b) APOC-III after injection of extracted peptides from FAU- zeolite 
nanoparticles. The peptide sequence derived from the two spectra are GWVTDGFSSLKDYWSTVK 
(APOC-III) and DSHSLTTNIMEILR (fibrinogen α -chain), respectively.
Figure 6. (a) Crystal structure of fibrinogen (crystal structure was used from PDB entry 3GHG),  
(b) schematic diagram of fibrinogen structure showing the flexibility of positively charged α C-domain. The 
amino acid sequence of α C-domain, amino acid residues 392–610, is shown below the diagram.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:17259 | DOI: 10.1038/srep17259
Upon treatment of 50% plasma for 30 min with 0.1% EMT- and FAU-zeolite nanoparticles, the clotting 
time is shortened with 5–7 seconds. One of the possibilities could be potentially due to the adsorption of 
fibrinogen to zeolite nanoparticles in the pooled plasma and hence, enhancing the rate of clot formation. 
The FAU-zeolite nanoparticles with higher surface area, higher total pore volume and higher surface 
charge density show clotting time of 18 sec, while for the EMT- zeolite nanoparticles is 16 sec. This indi-
cates that EMT-zeolite nanoparticles with higher hydrophilicity (Si/Al ratio of 1.14) are more selectively 
in interacting with the fibrinogens and leads to enrichment of fibrinogens in blood, which is essential in 
blood clotting. Thus, these NPs accelerate the time of blood clot formation and the mechanism whereby 
these NPs accelerate coagulation remains to be elucidated.
Discussion
Nanosized EMT- and FAU-zeolites open the possibility to use them in new biological and clinical appli-
cations (biological fluid)35–37. Of note, proteins are one of the most important components of biological 
fluid such as plasma system (sub-fraction of blood) and the interactions with zeolite nanoparticles is 
important to be studied prior further use.
There are ignorable differences in the number of identified proteins bound on the surface of the EMT- 
and FAU-zeolite nanoparticles (at 4% NPs) when they were exposed to 10% plasma proteins, and this 
could be due to (1) the low abundant proteins present in diluted plasma, and (2) no real competition 
between proteins during the adsorption on zeolite nanoparticles with large external surface. The latter 
phenomenon could be mediated by the presence of a few very high-abundance proteins albumin and 
immunoglobulin G (IgG)38–40, which are responsible for the constitution of 70% and 20% of plasma pro-
teins, respectively. This is the reason why the two major proteins in the EMT- and FAU-corona (protein 
layer of nanoparticles) exposed to 10% plasma only are albumin and IgG. It should be noted that the 
two major functions of albumin are binding and transporting the materials41. Importantly, the number 
of proteins present in the corona of zeolite nanoparticles is much less at 100% plasma exposure (in vivo 
state) than with 10% plasma. Therefore the assumption that there is a competition between proteins to 
occupy the corona of the zeolite nanoparticles is reasonable. Thus, the protein composition of corona in 
EMT- and FAU-zeolite nanoparticles appeared to be more dependent on plasma concentration and the 
type of zeolite (e.g. may be the external surface area of zeolite crystals) than NPs concentrations with 
respect to APOC-III, IGHG1, IGHG2 and IGHG3. Since EMT-zeolite nanoparticles are more hydro-
philic than FAU-zeolite nanoparticles, it is possible to assume that the high adsorption on EMT- zeolite 
may be due to the hydrophilicity.
Selective adsorption of APOC-III and fibrinogen on the surface of EMT- and FAU-zeolite nan-
oparticles. The selective adsorption of APOC-III on the surface of EMT- and FAU-zeolite nanopar-
ticles is most likely via electrostatic interactions between the solvent exposed positively charged amino 
acid residues of APOC-III and the negatively charged EMT- and FAU-zeolites. Specifically, there are two 
regions in the structures of APOC-III, that the side chains of amino acid residues are solvent exposed, 
and thus they can electrostatically interact with the negatively charged zeolite nanocrystals (Figure S2). 
The region including amino acid residues Lys17, His18, Lys21 and Lys24, and the area containing the 
Figure 7. The effect of EMT- and FAU-zeolite nanoparticles on clotting time: prothrombin test (PT) is 
performed in pooled plasma with and without EMT- and FAU-zeolite nanoparticles (incubation for 30 min) 
in KC-10 coagulometer. Clotting time is expressed in seconds (Sec). Zeolite nanoparticles (0.1% and 0.4%) 
are incubated in 100 μ l of 100% pooled plasma.
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solvent exposed amino acid residues Lys51, Lys58 and Lys60 are highly effective in binding to the neg-
atively charged EMT- and FAU-zeolite nanoparticles42. Furthermore, APOC-III is an inhibitor of LPL 
activation and it is considered as a risk factor for cardiovascular diseases. The two types zeolites can 
potentially be used for selectively capture of APOC-III, and to reduce the activation of lipoprotein lipase 
inhibition in hypertriglyceridemia treatment.
The application of in vivo plasma proteins (i.e. 100%) appeared to be essential for a strong bind-
ing of fibrinogen (all three chains) to the EMT- and FAU-zeolite nanoparticles. Fibrinogen D and E 
domains are rich in aspartic acid (Asp) and glutamic acid (Glu) residues, and these sections are negatively 
charged. In contrast, the α C-domain (remaining part of carboxyl terminal of both alpha chains, which 
are not present in D domain) is positively charged because this region is rich in arginine (Arg) and 
lysine (Lys). The fibrinogen is a dipolar molecule and it can be one of the potential reasons that facilitate 
the adsorption of fibrinogen on the surface of negatively charged EMT- and FAU-zeolite nanoparticles. 
Importantly, a maximum concentration of fibrinogen is a guarantee for its strong adsorption to both 
zeolite nanoparticles. Since these two nanoparticles are negatively charged, it is possible that fibrinogen 
is linked to the surface of the zeolite nanoparticles via α C-domains, which are positively charged. Other 
possibility is that the fibrinogen molecules, which are dipolar (D and E domains are negatively charged 
and α C-domain positively charged) and very stable, and hold tightly together. Most likely, the positive 
charged fibrinogen domain binds to the zeolite nanoparticles.
Effect of EMT- and FAU-zeolite nanoparticles on coagulation. It is very important to shed light 
on the role of the zeolite nanoparticles in biological functions such as coagulation system, which play 
an important role in wound healing process. Since the EMT- and FAU-zeolite nanoparticles show a very 
high selectivity for fibrinogen, it is necessary to measure the effect of these zeolite nanoparticles on fibrin 
formation. Notably, both zeolite nanoparticles accelerate the fibrin forming process. This property of 
the EMT- and FAU-zeolite nanoparticles can be adapted to hemophilic patients (hemophilia A (F-VIII 
deficient) and hemophilia B (F-IX deficient)) with a risk of bleeding. The present therapy of such patients 
is based on treatment with F-VIII extracts. Thus, the EMT- and FAU-zeolite nanoparticles might be 
potentially used as a complementary therapy in combination with the existing one.
Conclusions
This study provides an evidence for high specific adsorption of APOC-III and fibrinogen on EMT- 
and FAU-zeolite nanoparticles. There are three factors, that determine the protein content of corona; 
1- plasma concentrations, 2- the type of zeolite NPs (external surface area and hydrophilicity of zeolite 
nanocrystals), and 3- NPs concentrations (but less effect). Moreover, it was found that these NPs acceler-
ate the time of blood clot formation, which can be adapted to hemophilic patients (hemophilia A (F-VIII 
deficient) and hemophilia B (F-IX deficient)) with a risk of bleeding, and thus might be potentially used 
in combination with the existing therapy. Also, the zeolite nanoparticles can potentially be used for 
selectively capture of APOC-III in order to reduce the activation of lipoprotein lipase inhibition during 
hypertriglyceridemia treatment.
Experimental section
Synthesis and characterization of EMT- and FAU-zeolite nanoparticles. The EMT-zeolite nan-
oparticles with a diameter of 8‒12 nm were synthesized from a clear precursor suspension with a molar 
composition of 18.45Na2O: 5.15SiO2: 1Al2O3: 240.3H2O35. This suspension was subjected to hydrother-
mal synthesis at 30 °C for 36 h. The crystalline EMT-zeolite nanoparticles were then purified by a high-
speed centrifugation (75465 × g for 2 h) and re-dispersed in double distilled water; this procedure was 
repeated six times until the final colloidal suspension has a pH of 7.0; the solid concentration of EMT-
zeolite nanoparticles was adjusted to 5 wt%.
The FAU-zeolite nanoparticles with a diameter of 8–12 nm were synthesized from a clear precursor 
suspension with a molar composition: 9Na2O: 10SiO2: 0.7Al2O3: 160H2O43. The suspension was sub-
jected to hydrothermal synthesis at 50 °C for 45 h. The FAU-zeolite nanoparticles were then purified by a 
high-speed centrifugation (75465 × g for 2 h) and re-dispersed in double distilled water; this procedure 
was repeated three times until the final colloidal suspensions have a pH of 7.0; the solid concentration 
of FAU-nanoparticles was then adjusted to 5 wt%.
The chemical compositions of zeolite nanocrystals were determined by X-ray fluorescence (XRF) 
spectroscopy using a MagiX PHILIPS PW2540FEI. Transmission electron microscope (TEM) and scan-
ning electron microscope (SEM) operating at 300 kV and 30 kV using a JEOL and a Philips XL-30, 
respectively were applied to study the crystalline EMT- and FAU-zeolite nanoparticles. The hydrody-
namic diameters and zeta potential of the zeolite nanoparticles in the suspensions were determined with 
a Malvern Zetasizer Nano. The samples were first re-suspended in 10 mL of 1.0 mM KCl and the zeta 
potential of the particles was recorded. The surface charge density, σ , is calculated from the Grahame 
equation44:
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where, ε ε 0 is the dielectric permittivity of zeolite (FAU = 1.3458 × 10−11 AsV−1 m−1, EMT = 1.3547 × 10−11 
AsV−1 m−1), kB is the Boltzmann constant (1.381 × 10−23 JK−1), ψ 0 is the surface potential or zeta poten-
tial of the zeolite suspensions in 1.0 mM KCl, e is the electronic charge (1.602 × 10 −19 C), T is the absolute 
temperature (298 K), NA is the Avogadro’s number (6.022 × 1023 mol−1) and M1:1 is the concentration of 
KCl (1.0 mM). The surface charge of zeolite nanoparticles, Q, was calculated using the following equation:
σ
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where, σ is the surface charge density, SBET is the specific surface area, and Si/Al ratio is the silicon to 
aluminum ratio of the zeolite nanoparticles.
The porosity of zeolite nanoparticles were measured via adsorption and desorption of nitrogen using 
micrometrics ASAP 2010 volumetric adsorption analyzer. Samples were degassed at 250 °C under vac-
uum overnight prior to the measurement. The external surface area and micropore volume were esti-
mated by alpha-plot method using Silica-1000 (22.1 m2 g−1) as a reference.
Collection of plasma. Informed consent was obtained from all subjects and this was approved 
by the Medical Ethical Committee of the Academic Medical Center Amsterdam under number 
W11_084/#11.17.864. The methods were carried out in accordance with the approved international 
guidelines. Blood was collected from healthy volunteers in tubes containing sodium citrate (Na3C6H5O7, 
Becton Dickson & Co., The Netherlands) as anticoagulant. Thereafter, the blood was centrifuged at 
1500 × g for 20 min at 4 °C to collect plasma and subsequently all plasma samples were pooled and 
stored at − 80 °C for further analysis.
Semi-quantitative assessment of each protein presents on corona zeolite nanoparticles. A 
semi-quantitative assessment of the protein amounts was conducted through the application of the spec-
tral counting (SpC), based on the following equation12,25:
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where NpSpCk is the normalized percentage of the spectral count for protein k, SpC is the spectral count 
identified, and Mw is the molecular weight (kDa) of protein k. The SpC of each identified protein was 
normalized to the protein mass and expressed as the relative quantity of protein. This correction is based 
on the protein size and evaluates the real contribution of each protein present in the corona of zeolite 
nanoparticles.
In order to identify the proteins with high affinity towards EMT- and FAU-zeolite nanoparticles, 
different concentrations of zeolite nanoparticles (4 and 12 wt%) were incubated for 60 min with different 
human plasma concentrations (10 and 100%). For comparison, two blank samples were applied: (1) 
Milli-Q water containing 1% formic acid, and (2) 100 μ L nanoparticles were incubated with Milli-Q water 
containing 1% formic acid. After the incubations, all samples were centrifuged three times (24000 × g for 
30 min) to remove the free plasma. Subsequently, all samples were subjected to tryptic digestion (trypsin: 
100 ng/sample) at 37 °C for 24 h. Then the samples were centrifuged at 24000 × g for 60 min. The peptides 
were collected, and the zeolite nanoparticles were again re-suspended in 20 μ L Milli-Q water containing 
2% formic acid (three times vortexed during 45 min incubation and centrifuged at 24000 × g for 30 min). 
Finally, the peptides were collected and added to the first elution. All samples were then reduced with 
1% dithiothreitol to break disulfide bridges. Finally, 2 μ L of each sample-derived peptides fraction was 
injected into nLC-MS/MS (LTQ-ORBITRAP-XL). For each sample, two or three experiments were per-
formed, measured by nLC-MS/MS to ensure high accuracy in the analysis.
The peptides were analyzed by nLC-MS/MS on an Ultimate 3000 system (Dionex, Amsterdam, The 
Netherlands) interfaced online with a LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, 
San Jose, CA). Re-dissolved peptides were loaded onto a trapping microcolumn (5 mm × 300 μ m i.d.) 
packed with C18 PepMAP100 particles (5 μ m, Dionex) in 0.1% formic acid at a flow rate of 20 μ L min−1. 
Upon loading and washing, the peptides were back flush eluted onto a nano-column (15 cm × 75 μ m 
i.d.) packed with C18 PepMAP100 particles (3 μ m, Dionex). The following mobile phase gradient was 
executed at a flow rate of 300 nL min−1: 5–50% of solvent B in 93 min; 50–80% B in 5 min; 80% B for 
10 min, and back to 5% B in 5 min. Solvent A was 100:0 H2O–acetonitrile (v/v) with 0.1% formic acid, 
and solvent B was 10:90 H2O–acetonitrile (v/v) with 0.1% formic acid. Peptides were infused in the mass 
spectrometer via a dynamic nano-spray probe (Thermo Electron Corp.) with a stainless steel emitter 
(Proxeon, Odense, DK). The typical spray voltage was 1.6 kV with no sheath and auxiliary gas flow; the 
ion transfer tube temperature was 200 °C. The mass spectrometer was operated in data-dependent mode. 
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Automated gain control (AGC) was set to 5 × 105 charges and 1 × 104 charges for MS/MS at the linear 
ion trap analyzer. The Data Dependent Acquisition (DDA) cycle consisted of the survey scan within 
m/z 300–1300 at the orbitrap analyzer with target mass resolution of 60000 (full width half maximum 
at m/z 400) followed by MS/MS fragmentation of the five most intense precursor ions under the relative 
collision energy of 35% in the linear trap. Singly charged ions were excluded from MS/MS experiments, 
and m/z of fragmented precursor ions were dynamically excluded for 90 s. The ion selection threshold 
for triggering MS/MS experiments was set to 500 counts. An activation parameter, q, of 0.25 and an 
activation time of 30 ms were applied.
PEAKS DB45 (version 6.1) was applied to analyze the spectra/sample generated by nLC-MS/MS to 
identify proteins that bind to the layer (corona) of EMT- and FAU-zeolite nanoparticles. The total spectra 
per protein were determined by PEAKS DB to calculate the NpSpCk values. The structure of APOC-III 
and fibrinogen were drawn with PyMOL46.
Effect of EMT- and FAU-zeolite on coagulation: prothrombin time (PT). To measure the time 
that is needed to clot the plasma portion of blood, prothrombin test (PT) was performed in pooled 
plasma with and without EMT- and FAU-zeolite nanoparticles in a KC-10 coagulometer. Three con-
centrations of EMT- and FAU-zeolite nanoparticles (0, 0.1 and 0.4%) were incubated with 100% pooled 
plasma derived from healthy volunteers for 30 min at room temperature and vortexed very gentle inter-
mittently. Thereafter, prothrombin reagent was 10 times diluted; it contains a tissue factor and Ca2+ pro-
viding calcium ions supplement in the solution kept at 37 °C. From this reagent, 100 μ L was added to 
each sample to start the reaction. The time between the addition of the thrombin and the clot formation 
is recorded as the thrombin clotting time (Sec).
References
1. Valtchev, V. & Tosheva, L. Porous Nanosized Particles: Preparation, Properties, and Applications. Chem. Rev. 113, 6734–6760 
(2013).
2. Mintova, S., Gilson, J.-P. & Valtchev, V. Advances in nanosized zeolites. Nanoscale 5, 6693–6703 (2013).
3. Wu, J. et al. Protein adsorption onto nanozeolite: effect of micropore openings. J. Colloid Interf. Sci. 406, 130–138 (2013).
4. Zhang, Y. et al. Zeolite/polymer composite hollow microspheres containing antibiotics and the in vitro drug release. Journal of 
biomaterials science. Polymer edition 22, 809–822 (2011).
5. Young, S. W. et al. Gadolinium zeolite as an oral contrast agent for magnetic resonance imaging. Journal of magnetic resonance 
imaging: J. Magn. Reson. Imaging 5, 499–508 (1995).
6. Flores-López, N. S. et al. Synthesis and properties of crystalline silver nanoparticles supported in natural zeolite chabazite. J. Mol. 
Struct. 1028, 110–115 (2012).
7. Tavolaro, A., Riccio, I. I. & Tavolaro, P. Hydrothermal synthesis of zeolite composite membranes and crystals as potential vectors 
for drug-delivering biomaterials. Micropor. Mesopor. Mater. 167, 62–70 (2013).
8. Yu, T. et al. Controlled nanozeolite-assembled electrode: remarkable enzyme-immobilization ability and high sensitivity as 
biosensor. Chemistry 12, 1137–1143 (2006).
9. Ji, J. et al. Enhanced protein digestion through the confinement of nanozeolite-assembled microchip reactors. Anal. Chem. 80, 
2457–2463 (2008).
10. Hu, Y.-Y., Zhang, Y.-H., Ren, N. & Tang, Y. Crystal Plane- and Size-Dependent Protein Adsorption on Nanozeolite. J. Phys. Chem. C 
113, 18040–18046 (2009).
11. Baerlocher, C., McCusker, L. & Olson, D. Atlas of zeolite framework types. Elsevier Science B.V., 2007).
12. Laurent, S. et al. Corona protein composition and cytotoxicity evaluation of ultra-small zeolites synthesized from template free 
precursor suspensions. Toxicol. Res. 2, 270–279 (2013).
13. Rezaee, F., Maas, a., Verheijen, J. H. & Koopman, J. Increased hepatic fibrinogen Bbeta-gene transcription is not enough to 
increase plasma fibrinogen levels. A transgenic mouse study. Thromb. Haemostasis 85, 1025–1030 (2001).
14. Rezaee, F. et al. Overexpression of fibrinogen in ApoE*3-Leiden transgenic mice does not influence the progression of diet-
induced atherosclerosis. Thromb. Haemostasis 88, 329–334 (2002).
15. Gulledge, A. A., Rezaee, F., Verheijen, J. H. & Lord, S. T. A Novel Transgenic Mouse Model of Hyperfibrinogenemia. Thromb. 
Haemostasis 86, 511–516 (2001).
16. Farrell, D., Mulvihill, E. & Huang, S. Recombinant human fibrinogen and sulfation of the gamma’ chain. Biochem. 30, 9414–9420 
(1991).
17. Wolfenstein-Todel, C. & Mosesson, M. W. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal 
sequence in a normal gamma chain variant (gamma’). P. Natl. Acad. Sci. USA 77, 5069–5073 (1980).
18. Redman, C. Fibrinogen Assembly and Secretion. ROLE OF INTRACHAIN DISULFIDE LOOPS. J. Biol. Chem. 271, 30083–30088 
(1996).
19. Meijer, K. et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of 
macrophages. PloS one 6, e17154 (2011).
20. Segrest, J. P. et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. 
J. Lipid Res. 33, 141–166 (1992).
21. Zdunek, J. et al. Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased 
mobility of the helix involved in the activation of lipoprotein lipase. Biochem. 42, 1872–1889 (2003).
22. Lins, L. et al. Lipid-interacting properties of the N-terminal domain of human apolipoprotein C-III. Protein Eng. 15, 513–520 
(2002).
23. Vaz, W. L., Jacobson, K., Wu, E. S. & Derzko, Z. Lateral mobility of an amphipathic apolipoprotein, ApoC-III, bound to 
phosphatidylcholine bilayers with and without cholesterol. Proceedings of the National Academy of Sciences of the United States 
of America 76, 5645–5649 (1979).
24. Assmann, G. & Brewer, H. B. A molecular model of high density lipoproteins. P. Natl. Acad. Sci. USA 71, 1534–1538 (1974).
25. Monopoli, M. P. et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of 
nanoparticles. J. Am. Chem. Soc. 133, 2525–2534 (2011).
26. Walczyk, D., Bombelli, F. B., Monopoli, M. P., Lynch, I. & Dawson, K. A. What the cell “sees” in bionanoscience. J. Am. Chem. 
Soc. 132, 5761–5768 (2010).
www.nature.com/scientificreports/
1 2Scientific RepoRts | 5:17259 | DOI: 10.1038/srep17259
27. Mahmoudi, M. et al. Crucial role of the protein corona for the specific targeting of nanoparticles.Nanomedicine 10, 215–226 
(2015).
28. Behzadi, S. et al. Protein corona change the drug release profile of nanocarriers: The “overlooked” factor at the nanobio interface. 
Colloids Surf. B Biointerfaces 123, 143–149 (2014).
29. Sakulkhu, U., Mahmoudi, M., Maurizi, L., Salaklang, J. & Hofmann, H. Protein Corona Composition of Superparamagnetic Iron 
Oxide Nanoparticleswith Various Physico-Chemical Properties and Coatings. Sci. Rep. 4, 5020 (2014).
30. Hajipour, M. J., Laurent, S., Aghaie, A., Rezaee, F. & Mahmoudi, M. Personalized protein coronas: a “key” factor at the 
nanobiointerface. Biomater. Sci. 4, 1210–1221 (2014).
31. Kollman, J. M., Pandi, L., Sawaya, M. R., Riley, M. & Doolittle, R. F. Crystal structure of human fibrinogen. Biochem. 48, 
3877–3886 (2009).
32. Marsh, J. J. et al. Structural insights into fibrinogen dynamics using amide hydrogen/deuterium exchange mass spectrometry. 
Biochem. 52, 5491–5502 (2013).
33. Adamczyk, Z. et al. Fibrinogen conformations and charge in electrolyte solutions derived from DLS and dynamic viscosity 
measurements. J. Colloid Interf. Sci. 385, 244–257 (2012).
34. Lousinian, S., Missopolinou, D. & Panayiotou, C. Fibrinogen adsorption on zinc oxide nanoparticles: a Micro-Differential 
Scanning Calorimetry analysis. J. Colloid Interf. Sci. 395, 294–299 (2013).
35. Ng, E.-P., Chateigner, D., Bein, T., Valtchev, V. & Mintova, S. Capturing ultrasmall EMT zeolite from template-free systems. 
Science 335, 70–73 (2012).
36. Pérez-Ramírez, J. Zeolite nanosystems: Imagination has no limits. Nat. Chem. 4, 250–251 (2012).
37. Drechsler, A. & Grundke, K. The influence of electrolyte ions on the interaction forces between polystyrene surfaces. Colloid. 
Surface A 264, 157–165 (2005).
38. Rezaee, F., Casetta, B., Levels, J. H. M., Speijer, D. & Meijers, J. C. M. Proteomic analysis of high-density lipoprotein. Proteomics 
6, 721–730 (2006).
39. Queiroz, K. C. S. et al. Human plasma very low density lipoprotein carries Indian hedgehog. J. Proteome Res. 9, 6052–6059 
(2010).
40. Sharifi, S. et al. Superparamagnetic iron oxide nanoparticles alter expression of obesity and T2D-associated risk genes in human 
adipocytes. Sci. Rep. 3, 2173 (2013).
41. Klammt, S. et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with 
severity of liver disease assessed by model for end-stage liver disease. Eur. J. Gastroenterol. Hepatol. 19, 257–263 (2007).
42. Gangabadage, C. S. et al. Structure and dynamics of human apolipoprotein CIII. J. Biol. Chem. 283, 17416–17427 (2008).
43. Awala, H. et al. Template-free nanosized faujasite-type zeolites. Nat. Mater. 14, 447–551 (2015).
44. Shan, X. et al. Measuring surface charge density and particle height using surface plasmon resonance technique. Anal. Chem. 82, 
234–240 (2010).
45. Zhang, J. et al. PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide identification. Mol. 
Cel. Proteomics 11, M111. 010587 (2012).
46. DeLano, W. L. The PyMOL Molecular Graphics System. Schrödinger LLC wwwpymolorg (Version 1.7.4.): http://www.pymol.org 
(2002).
Author Contributions
M.R. and F.R. wrote the paper. F.R. conceived, designed and supervised the study. All authors (K.B., E.P.N., 
M.V., H.A.A., S.M., M.D., F.B., M.D.V., M.M.Z., M.P.P., M.M. and F.R.) involved in the experiments and 
generation of data as well as edition of the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The financial support from the Region of Lower Normandy, the Zeoxy 
project is acknowledged for financial support. The financial support from Erasmus Medical Center, 
Rotterdam, The Netherlands.
How to cite this article: Rahimi, M. et al. Zeolite Nanoparticles for Selective Sorption of Plasma 
Proteins. Sci. Rep. 5, 17259; doi: 10.1038/srep17259 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
